EXEL · XBRL financial data

Exelixis financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (EXEL's year ends in early January)

In millions of dollars	FY 2020Jan 1, 2021	FY 2021Dec 31, 2021	FY 2022Dec 30, 2022	FY 2023Dec 29, 2023	FY 2024Jan 3, 2025	FY 2025Jan 2, 2026
Revenue from contracts with customers	988	1,435	1,611	1,830	2,169	2,320
Cost of goods and services sold	36	53	58	73	76	84
Research and development	548	694	892	1,044	910	825
Selling, general and administrative	293	402	460	543	492	519
Operating income (loss)	110	287	201	171	605	872
Other income (expense)	1	(0)	(0)	0	(0)	(0)
Income tax expense (benefit)	19	63	52	50	160	159
Net income (loss)	112	231	182	208	521	783
Earnings per share, basic USD per share	0.36	0.73	0.57	0.65	1.80	2.88
Earnings per share, diluted USD per share	0.35	0.72	0.56	0.65	1.76	2.78
Weighted average shares, basic millions of shares	308	315	322	318	290	272
Weighted average shares, diluted millions of shares	318	322	325	321	296	282

Fiscal years (EXEL's year ends in early January)

In millions of dollars	FY 2020Jan 1, 2021	FY 2021Dec 31, 2021	FY 2022Dec 30, 2022	FY 2023Dec 29, 2023	FY 2024Jan 3, 2025	FY 2025Jan 2, 2026
Cash and cash equivalents	319	647	501	263	217	482
Short-term investments	887	820	807	732	—	—
Marketable securities	—	—	—	732	894	577
Marketable securities, non-current	—	—	—	729	637	604
Inventory	21	27	33	17	22	22
Prepaid and other current assets	57	58	62	68	68	76
Total current assets	1,445	1,835	1,619	1,318	1,468	1,443
Property and equipment, net	67	104	111	129	119	99
Right-of-use asset	43	45	235	233	173	159
Goodwill	64	64	64	64	64	64
Total assets	2,137	2,616	3,071	2,942	2,948	2,844
Accounts payable	24	24	33	34	38	30
Total current liabilities	205	338	324	394	404	406
Lease liability, non-current	49	51	190	190	191	173
Total liabilities	258	406	583	678	703	683
Accumulated deficit	(448)	(217)	(34)	(173)	(99)	(77)
Total stockholders' equity	1,879	2,211	2,488	2,264	2,244	2,161
Total liabilities and equity	2,137	2,616	3,071	2,942	2,948	2,844
Common shares outstanding (cover page) millions of shares	312	319	324	303	280	260

Fiscal years (EXEL's year ends in early January)

In millions of dollars	FY 2020Jan 1, 2021	FY 2021Dec 31, 2021	FY 2022Dec 30, 2022	FY 2023Dec 29, 2023	FY 2024Jan 3, 2025	FY 2025Jan 2, 2026
Net income (loss)	112	231	182	208	521	783
Stock-based compensation	105	120	108	106	94	113
Depreciation and amortization	9	14	21	26	29	29
Net cash from operating activities	209	401	363	333	700	884
Purchases of property and equipment	30	64	28	40	28	8
Net cash from investing activities	(131)	(43)	(524)	(27)	(117)	350
Share repurchases	—	0	0	550	652	948
Net cash from financing activities	(25)	(15)	1	(546)	(629)	(970)
Net change in cash	53	343	(161)	(240)	(46)	265

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Exelixis	305	659	280*	244.0M	—	Q3 FY26 10-QOct 2, 2026
Neurocrine Biosciences	642	1,123	395*	101.2M	—	Q3 FY26 10-QSep 30, 2026
BIO-TECHNE	265	321*	95*	156.8M	—	Q4 FY26 10-KJun 30, 2026
Roivant Sciences	1,248	1.4	(271)	722.3M	14.2 quarters	Q1 FY26 10-QJun 30, 2026
United Therapeutics	1,803	783	314*	42.9M	—	Q2 FY26 10-QJun 30, 2026
Revolution Medicines	815	not reported	(387)*	214.3M	10.2 quarters	Q2 FY26 10-QJun 30, 2026
Biomarin Pharmaceutical	736	1,025	188*	193.7M	—	Q3 FY26 10-QSep 30, 2026
Jazz Pharmaceuticals	2,036	1,243	506*	64.2M	—	Q3 FY26 10-QSep 30, 2026
Corcept Therapeutics	99	340	143*	109.4M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.